Loading
NASDAQHealthcareMedical - Devices
Latest quote
$58.84
+$0.92 · +1.59%
Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.
Latest quote
$58.84
+$0.92 · +1.59%
After-hours
$58.84
$0.00 · 0.00%
Oct 9, 4:04 PM ET
Regular session · ET · Market data may be delayed.
Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.
Day range
Current $58.84
52-week range
Current $58.84
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
18
Overpriced
Sentiment
60
Mixed
Risk
44
Elevated Risk
Momentum
61
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.
Day range
Current $58.84
52-week range
Current $58.84
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 3.44B USD | 3.37B USD | 2.96B USD | 2.53B USD | 2.42B USD |
| Cost of goods sold | 1.86B USD | 1.72B USD | 1.45B USD | 1.23B USD | 1.21B USD |
| Gross profit | 1.58B USD | 1.65B USD | 1.51B USD | 1.31B USD | 1.21B USD |
| Research and development | 395.2M USD | 376.5M USD | 294.8M USD | 235.9M USD | 220.8M USD |
| Selling, general, and administrative | 946.5M USD | 893.8M USD | 729.4M USD | 607.4M USD | 562.3M USD |
| Operating expenses | 1.34B USD | 1.4B USD | 1.08B USD | 873M USD | 796.3M USD |
| Interest income | 14.8M USD | 9.3M USD | 7.5M USD | 2.8M USD | 900K USD |
| Interest expense | 60.3M USD | 47.9M USD | 16.4M USD | 16.1M USD | 14.3M USD |
| Depreciation and amortization | 220.3M USD | 183.8M USD | 114.9M USD | 88.7M USD | 89.1M USD |
| Operating income | 236M USD | 253.1M USD | 436.9M USD | 432.7M USD | 413.3M USD |
| Net income | −8.6M USD | 113.1M USD | 427.2M USD | 296.6M USD | 277.1M USD |
Company facts updated Oct 9, 2026.
Third-party consensus; not a GoAI recommendation.
Average target
$67.00
13.87% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI196.51M0.01%2.3T USD0.03%$381.92+0.62%
Vanguard Morningstar Small-Cap ETFVB142.29M0.08%185.3B USD0.03%$289.48+0.64%
Vanguard Morningstar Small-Cap Value ETFVBR90.32M0.13%68.2B USD0.05%$234.39+0.21%
First Trust NYSE Arca Biotechnology Index FundFBT87.31M3.08%2.87B USD0.55%$265.29+1.96%
Vanguard Extended Market ETFVXF74.93M0.08%95.4B USD0.05%$235.04+0.82%
Dimensional - US Small Cap ETFDFAS63.62M0.19%33.8B USD0.31%$78.35+0.32%
iShares Biotechnology ETFIBB49.83M0.47%10.41B USD0.44%$206.49+3.00%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY47.76M0.19%25.53B USD0.23%$669.78+0.53%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Value ETFVBRFirst Trust NYSE Arca Biotechnology Index FundFBTVanguard Extended Market ETFVXFDimensional - US Small Cap ETFDFASiShares Biotechnology ETFIBBState Street SPDR S&P MIDCAP 400 ETF TrustMDYAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
